Latest On Synthetic Biologics, Inc (SYN):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2022-09-27 17:24 EST | News | Safety board recommends Synthetic Biologics proceed in cell transplant recipients trial | N/A |  |
| 2022-09-06 15:24 EST | News | Synthetic Biologics VCN-01 shows safety in phase 1 trial in head/neck cancer | N/A | |
| 2022-08-11 16:05 EST | News | Synthetic Biologics GAAP EPS of -$0.31 | N/A | |
| 2022-08-11 16:04 EST | News | Synthetic Biologics, Inc. (SYN) CEO Steven Shallcross on Q2 2022 Results - Earnings Call Transcript | N/A | |
| 2022-08-10 23:57 EST | News | Synthetic Biologics Q2 2022 Earnings Preview | N/A | |
| 2022-07-15 20:16 EST | News | Synthetic Biologics stock slides on reverse stock split announcement | N/A | |
| 2022-05-16 19:40 EST | News | Synthetic Biologics GAAP EPS of -$0.03 in-line | N/A | |
| 2022-05-16 19:39 EST | News | Synthetic Biologics, Inc. (SYN) CEO Steven Shallcross on Q1 2022 Results - Earnings Call Transcript | N/A | |
| 2022-05-10 14:29 EST | News | Synthetic Biologics stock rises as oral drug SYN-020 shows safety in early-stage study | N/A | |
| 2022-03-17 23:24 EST | News | Synthetic Biologics GAAP EPS of -$0.19 misses by $0.01 | N/A | |
| 2022-03-17 23:24 EST | News | Synthetic Biologics, Inc. (SYN) CEO Steven Shallcross on Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2022-03-16 12:27 EST | News | Synthetic Biologics FY 2021 Earnings Preview | N/A | |
| 2022-02-09 01:08 EST | News | Synthetic Biologics says VCN's therapy for retinoblastoma gets FDA's orphan drug status | N/A | |
| 2021-12-14 22:23 EST | News | Synthetic Biologics to acquire VCN Biosciences for over $4M in upfront cash | N/A | |
| 2021-11-03 19:30 EST | News | Synthetic Biologics EPS beats by $0.01 | N/A | |
| 2021-11-03 19:29 EST | News | Synthetic Biologics, Inc.'s (SYN) CEO Steven Shallcross on Q3 2021 Results - Earnings Call Transcript | N/A | |
| 2021-10-21 17:39 EST | News | Synthetic Biologics initiates early-stage trial for SYN-020 intestinal alkaline phosphatase | N/A | |
| 2021-08-06 11:13 EST | News | Synthetic Biologics, Inc. (SYN) CEO Steven Shallcross on Q2 2021 Results - Earnings Call Transcript | N/A | |
| 2021-05-05 23:52 EST | News | Synthetic Biologics reports Q1 results | N/A | |
| 2021-05-05 23:51 EST | News | Synthetic Biologics' (SYN) CEO Steven Shallcross on Q1 2021 Results - Earnings Call Transcript | N/A | |
| 2021-05-04 06:21 EST | News | Synthetic Biologics files for $300M mixed shelf offering | N/A | |
| 2021-04-01 23:40 EST | News | Dosing underway in Synthetic Bio's early-stage SYN-020 study in intestinal alkaline phosphatase | N/A | |
| 2021-03-23 10:37 EST | News | Sizing Up Synthetic Biologics | N/A | |
| 2021-03-16 22:09 EST | Analyst Rating | The Analyst Target Price has increased from $1.25 to $1.88. | Buy | |
| 2021-03-09 08:41 EST | Earnings Estimate | An EPS average of -$0.03 is estimated for the quarter ending on June 30, 2021. | Buy | |
| 2021-03-06 08:39 EST | Financials | Company financials have been released. | Neutral | |
| 2021-03-05 08:42 EST | Earnings Estimate | An EPS average of -$0.19 is estimated for the 2022 year. | Sell | |
| 2021-03-05 05:48 EST | News | Synthetic Biologics EPS misses by $0.10 | N/A | |
| 2021-03-05 05:48 EST | News | Synthetic Biologics, Inc's (SYN) CEO Steve Shallcross on Q4 2020 Results - Earnings Call Transcript | N/A | |
| 2020-12-23 02:33 EST | News | Synthetic Biologics on go with early-stage study with SYN-004 | N/A | |
| 2020-11-26 21:42 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-14 05:30 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-13 05:49 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-11 13:06 EST | Earnings Estimate | An EPS average of -$0.15 is estimated for the quarter ending on March 31, 2021. | Sell | |
| 2020-11-11 01:23 EST | News | Synthetic Biologics EPS beats by $0.03 | N/A | |
| 2020-11-11 01:23 EST | News | Synthetic Biologics, Inc. (SYN) CEO Steven Shallcross on Q3 2020 Results - Earnings Call Transcript | N/A | |
| 2020-11-08 01:01 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 17:16 EST | Financials | Company financials have been released. | Neutral | |
| 2020-10-05 06:12 EST | Analyst Rating | The Analyst Target Price has decreased from $1.38 to $1.25. | Neutral | |
| 2020-10-03 08:42 EST | News | Synthetic Bio's lead candidate flunks irritable bowel study; shares down 42% | N/A | |
| 2020-09-26 14:10 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 06:22 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-14 10:15 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-09 05:47 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-07 02:56 EST | News | Synthetic Biologics EPS in-line | N/A | |
| 2020-08-07 02:55 EST | News | Synthetic Biologics' (SYN) CEO Steven Shallcross on Q2 2020 Results - Earnings Call Transcript | N/A | |
| 2020-08-06 09:38 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-31 06:04 EST | News | Synthetic Biologics on go with first study of enzyme therapy for gut health | N/A | |
| 2020-07-30 17:59 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 05:57 EST | Financials | Company financials have been released. | Neutral | |
About Synthetic Biologics, Inc (SYN):
Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat gastrointestinal (GI) diseases in the United States. Its lead product candidates include SYN-004 that has completed Phase II clinical trial designed to degrade commonly used intravenous beta-lactam antibiotics in GI tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. The company also develops clinical stage products, such as SYN-006 and SYN-007 for the prevention of CDI, overgrowth of pathogenic organisms, and AMR; and SYN-005 for the prevention and treatment of pertussis. Synthetic Biologics, Inc. has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. The company is headquartered in Rockville, Maryland.
General
- Name Synthetic Biologics, Inc
- Symbol SYN
- Type Common Stock
- Exchange NYSE MKT
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 10
- Last Split Factor1:35
- Last Split Date2018-08-13
- Fiscal Year EndDecember
- IPO Date2006-06-26
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.syntheticbiologics.com
View More
Valuation
- Price/Book (Most Recent Quarter) 77.81
View More
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$0.09
- Next Year EPS Estimate -$0.12
- Return on Assets -50%
- Return on Equity -121%
- Earnings Per Share -$2.12
- Revenue Per Share $0
- Quarterly Earnings Growth 0%
View More
Highlights
- Market Capitalization 102.44 million
- EBITDA -14536000
- Analyst Target Price $1.88
- Book Value Per Share $0.01
View More
Share Statistics
- Shares Outstanding 129.66 million
- Shares Float 127.36 million
- % Held by Insiders 37%
- % Held by Institutions 7.12%
- Shares Short 9.74 million
- Shares Short Prior Month 1.97 million
- Short Ratio 0.54
- Short % of Float 9%
- Short % of Shares Outstanding 9%
View More
Technicals
- Beta 2.02
- 52 Week High $1.22
- 52 Week Low $0.28
- 50 Day Moving Average 0.81
- 200 Day Moving Average 0.55
View More
Dividends
- Dividend Date 2018-08-13
- ExDividend Date N/A
- Dividend Yield 0%
View More
Synthetic Biologics, Inc (SYN) Dividend Calendar:
SYN's last dividend payment was made to shareholders on August 13, 2018.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Synthetic Biologics, Inc (SYN) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-03-04 | $N/A | -$0.14 | -$0.08 | -75% |
| 2020-09-30 | 2020-11-10 | $N/A | -$0.14 | -$0.17 | 17.65% |
| 2020-06-30 | 2020-08-06 | $N/A | -$0.18 | -$0.18 | 0% |
| 2020-03-31 | 2020-05-05 | $N/A | -$0.20 | -$0.27 | 25.93% |
| 2019-12-31 | 2020-02-20 | $N/A | -$0.19 | -$0.23 | 17.39% |
| 2019-09-30 | 2019-11-04 | $N/A | -$0.31 | -$0.23 | -34.78% |
| 2019-06-30 | 2019-08-08 | $N/A | -$0.22 | -$0.23 | 4.35% |
| 2019-03-31 | 2019-05-08 | $N/A | -$0.22 | -$0.23 | 4.35% |
| 2018-12-31 | 2019-02-27 | $N/A | -$1.33 | -$0.20 | -582.05% |
| 2018-09-30 | 2018-11-08 | $N/A | -$0.93 | -$1.33 | 29.81% |
| 2018-06-30 | 2018-08-08 | $N/A | -$1.05 | -$1.40 | 25% |
| 2018-03-31 | 2018-05-08 | $N/A | -$0.70 | -$1.75 | 60% |
| 2017-12-31 | 2018-02-22 | $N/A | $0.70 | -$1.63 | 142.86% |
| 2017-09-30 | 2017-11-01 | $N/A | -$4.90 | -$1.52 | -223.07% |
| 2017-06-30 | 2017-08-03 | $N/A | -$1.05 | -$1.98 | 47.06% |
| 2017-03-31 | 2017-05-04 | $N/A | -$0.70 | -$2.57 | 72.73% |
| 2016-12-31 | 2017-03-02 | $N/A | -$0.70 | -$2.73 | 74.36% |
| 2016-09-30 | 2016-11-01 | $N/A | -$3.15 | -$3.68 | 14.29% |
| 2016-06-30 | 2016-08-03 | $N/A | -$2.10 | -$3.97 | 47.06% |
| 2016-03-31 | 2016-05-05 | $N/A | -$4.20 | -$4.64 | 9.43% |
| 2015-12-31 | 2016-03-10 | $N/A | -$4.20 | -$4.34 | 3.23% |
| 2015-09-30 | 2015-11-05 | $N/A | -$0.08 | -$0.12 | 33.33% |
| 2015-06-30 | 2015-08-10 | $N/A | -$0.19 | -$0.11 | -72.73% |
| 2015-03-31 | 2015-05-11 | $N/A | -$0.17 | -$0.08 | -112.5% |
| 2014-12-31 | 2015-03-16 | $N/A | -$0.09 | -$0.06 | -50% |
| 2014-09-30 | 2014-11-14 | $N/A | -$0.08 | -$0.05 | -60% |
| 2014-06-30 | 2014-08-14 | $N/A | -$2.80 | -$2.27 | -23.35% |
| 2014-03-31 | 2014-05-15 | $N/A | -$2.45 | -$2.68 | 8.58% |
| 2013-12-31 | 2014-03-31 | $N/A | -$3.15 | -$2.22 | -41.89% |
| 2013-09-30 | 2013-11-14 | $N/A | -$2.80 | -$2.01 | -39.3% |
| 2013-06-30 | 2013-08-14 | $N/A | -$2.10 | -$1.92 | -9.38% |
| 2013-03-31 | 2013-04-16 | $N/A | -$11.90 | -$1.23 | -867.48% |
| 2012-09-30 | 2012-11-20 | $N/A | -$2.02 | ||
| 2012-06-30 | 2012-08-13 | $N/A | -$1.98 | ||
| 2012-03-31 | 2012-05-15 | $N/A | -$1.31 | ||
| 2011-12-31 | 2012-03-30 | $N/A | -$3.85 | -$1.05 | -266.67% |
| 2011-09-30 | 2011-11-14 | $293421 | -$1.05 | -$1.40 | 25% |
| 2011-06-30 | 2011-08-15 | $355562 | -$2.11 | ||
| 2011-03-31 | 2011-05-16 | $N/A | -$3.03 | ||
| 2010-09-30 | 2010-11-15 | $290000 | -$1.12 | ||
| 2010-06-30 | 2010-08-16 | $2.2 million | $1.57 | ||
| 2010-03-31 | 2010-05-18 | $60000 | -$1.77 | ||
| 2009-12-31 | 2010-03-03 | $52000 | -$1.83 | ||
| 2009-09-30 | 2009-11-17 | $51000 | -$1.02 | ||
| 2009-06-30 | 2009-08-14 | $N/A | -$1.45 | ||
| 2009-03-31 | 2009-05-15 | $N/A | -$1.87 | ||
| 2008-12-31 | 2009-03-31 | $N/A | -$1.40 | -$2.45 | 42.86% |
| 2008-09-30 | 2008-11-14 | $N/A | -$2.41 | ||
| 2008-06-30 | 2008-08-14 | $N/A | -$3.15 | -$3.85 | 18.18% |
| 2008-03-31 | 2008-05-15 | $N/A | -$5.25 | -$4.90 | -7.14% |
| 2007-12-31 | 2008-03-31 | $N/A | -$8.05 | -$4.20 | -91.67% |
| 2007-09-30 | 2007-11-14 | $N/A | -$4.20 | -$4.20 | 0% |
| 2007-06-30 | 2007-08-13 | $N/A | -$3.50 | -$4.20 | 16.67% |
| 2007-03-31 | 2007-05-15 | $N/A | -$31.45 | ||
| 2006-12-31 | 2007-03-08 | $N/A | -$31.50 | ||
| 2006-09-30 | 2006-11-17 | $N/A | -$0.10 | ||
| 2006-06-30 | 2006-08-16 | $N/A | -$0.19 | ||
| 2006-03-31 | 2006-05-16 | $N/A | $0.00 | ||
| 2005-12-31 | 2006-03-09 | $N/A | -$1.08 | ||
| 2005-09-30 | 2005-11-18 | $N/A | -$1.14 | ||
| 2005-06-30 | 2005-08-17 | $N/A | $0.00 | ||
| 2005-03-31 | 2005-05-10 | $N/A | $0.00 | ||
| 2004-12-31 | 2005-03-10 | $0.00 | |||
| 2004-09-30 | 2004-11-12 | $0.00 | |||
| 2004-06-30 | 2004-08-11 | $0.00 | |||
| 2004-03-31 | 2004-05-11 | $0.00 | |||
| 2003-09-30 | 2003-11-14 | $0.00 | |||
| 2003-06-30 | 2003-08-13 | $14,420.73 | |||
| 2003-03-31 | 2003-05-13 | -$1,324.51 | |||
| 2002-09-30 | 2002-11-15 | -$1,691.31 | |||
| 2002-06-30 | 2002-08-14 | -$3,345.76 | |||
| 2002-03-31 | 2002-05-01 | -$3,333.51 | |||
| 2001-09-30 | 2001-11-01 | -$9.45 | -$5.25 | -80% | |
| 2001-06-30 | 2001-08-02 | -$8.40 | -$5.25 | -60% | |
| 2001-03-31 | 2001-03-31 | -$1,438.90 | |||
| 2000-09-30 | 2000-09-30 | -$1,231.18 | |||
| 2000-06-30 | 2000-06-30 | -$1,298.31 | |||
| 2000-03-31 | 2000-03-31 | -$1,386.23 | |||
| 1999-09-30 | 1999-11-09 | -$5.25 | -$3.15 | -66.67% | |
| 1999-06-30 | 1999-06-30 | -$1,430.88 | |||
| 1999-03-31 | 1999-03-31 | -$1,127.12 | |||
| 1998-09-30 | 1998-09-30 | -$2,093.62 | |||
| 1998-06-30 | 1998-06-30 | -$17,501.61 | |||
| 1998-03-31 | 1998-03-31 | -$4,395.58 | |||
| 1996-12-31 | 1997-03-27 | -$19.95 | -$16.80 | -18.75% |
Synthetic Biologics, Inc (SYN) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Research Development | 979000 | 914000 | N/A | 1.64 million | 1.93 million |
| Income Before Tax | -2.13 million | -2.11 million | N/A | -2.99 million | -3.14 million |
| Selling General Administrative | 1.15 million | 1.2 million | N/A | 1.39 million | 1.28 million |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Ebit | -2.13 million | -2.06 million | N/A | -2.97 million | -3.21 million |
| Operating Income | -2.13 million | -2.11 million | N/A | -3.03 million | -3.21 million |
| Income Tax Expense | N/A | N/A | N/A | N/A | N/A |
| Total Revenue | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A |
| Total Other Income Expense Net | N/A | N/A | N/A | N/A | 66000 |
| Net Income From Continuing Operations | -2.13 million | -2.11 million | N/A | -2.99 million | -3.14 million |
| Net Income Applicable to Common Shares | -3.12 million | N/A | -3.32 million | -3.43 million | -3.14 million |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | -4000 | N/A | N/A | N/A | N/A |
| Change to Liabilities | N/A | -222000 | -1.07 million | -137000 | 929000 |
| Total Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Net Borrowings | N/A | N/A | N/A | N/A | N/A |
| Total Cash Flow from Financial Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Operating Activities | N/A | 925000 | -1.07 million | -444000 | 966000 |
| Change in Cash | -2.05 million | N/A | -4.96 million | -3.61 million | -3.06 million |
| Total Cash from Operating Activities | -2.05 million | -2.03 million | -4.96 million | -3.61 million | -3.06 million |
| Depreciation | 53000 | N/A | 58000 | 58000 | 60000 |
| Other Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Inventory | N/A | N/A | N/A | N/A | N/A |
| Change to Account Receivables | N/A | N/A | N/A | N/A | N/A |
| Other Cash Flow from Financing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Net Income | N/A | 80000 | 109000 | 58000 | 103000 |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Total Liabailities | 3.15 million | 3.27 million | N/A | 3.28 million | 5.75 million |
| Total Stockholder Equity | -4.77 million | 6.68 million | N/A | 11.48 million | -2.94 million |
| Other Current Liabilities | 473000 | N/A | N/A | N/A | N/A |
| Total Assets | 8.41 million | 7.2 million | N/A | 11.89 million | 17.24 million |
| Common Stock | 29000 | N/A | 19000 | 18000 | 17000 |
| Other Current Assets | 1.71 million | N/A | N/A | N/A | 48000 |
| Retained Earnings | -248.09 million | -244.98 million | -242.29 million | -238.97 million | -235.54 million |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | N/A | 23000 | 23000 | 23000 |
| Cash | 6.23 million | 6.01 million | N/A | 10.09 million | 15.05 million |
| Total Current Liabilities | 2.97 million | 3.01 million | N/A | 2.88 million | 5.28 million |
| Other Stockholder Equity | N/A | N/A | N/A | N/A | N/A |
| Property, Plant & Equipment | 174000 | N/A | 603000 | 695000 | 786000 |
| Total Current Assets | 7.93 million | 6.66 million | N/A | 11.17 million | 16.43 million |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | 5.55 million | N/A | -7.41 million | -5.21 million | -2.94 million |
| Short Term Investments | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A |
| Inventory | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | 2.68 million | 992000 | N/A | 1.25 million | 2.32 million |
Synthetic Biologics, Inc (SYN) Chart:
Synthetic Biologics, Inc (SYN) News:
Below you will find a list of latest news for Synthetic Biologics, Inc (SYN) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Synthetic Biologics, Inc (SYN) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Latest SYN Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 4:19 PM EST | 22 | $0.1982 |
| Jun 13, 2022 4:35 PM EST | 100 | $0.2004 |
| Jun 13, 2022 4:35 PM EST | 100 | $0.2004 |
| Jun 13, 2022 4:35 PM EST | 100 | $0.2004 |
| Jun 13, 2022 7:23 PM EST | 200 | $0.2021 |
Synthetic Biologics, Inc (SYN) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-05-05 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/894158/000110465920056927/0001104659-20-056927-index.htm |
| 2018-05-15 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/894158/000000000018014999/0000000000-18-014999-index.htm |
| 2018-08-15 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/894158/000000000018025271/0000000000-18-025271-index.htm |
| 2018-09-25 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/894158/000000000018030213/0000000000-18-030213-index.htm |
| 2018-10-18 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/894158/000093041318003095/0000930413-18-003095-index.htm |
| 2019-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/894158/000093041319000505/0000930413-19-000505-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/894158/000093041320000372/0000930413-20-000372-index.htm |
| 2019-11-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/894158/000110465919059502/0001104659-19-059502-index.htm |
| 2019-11-04 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/894158/000110465919059538/0001104659-19-059538-index.htm |
| 2019-11-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/894158/000110465919068217/0001104659-19-068217-index.htm |
| 2019-12-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/894158/000110465919070212/0001104659-19-070212-index.htm |
| 2019-12-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/894158/000110465919070227/0001104659-19-070227-index.htm |
| 2019-12-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/894158/000110465919070228/0001104659-19-070228-index.htm |
| 2019-12-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/894158/000110465919070375/0001104659-19-070375-index.htm |
| 2019-12-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/894158/000110465919070376/0001104659-19-070376-index.htm |
| 2020-01-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/894158/000110465920001775/0001104659-20-001775-index.htm |
| 2020-02-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/894158/000110465920012556/0001104659-20-012556-index.htm |
| 2020-02-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/894158/000110465920023392/0001104659-20-023392-index.htm |
| 2020-02-20 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/894158/000110465920023415/0001104659-20-023415-index.htm |
| 2020-05-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/894158/000110465920056877/0001104659-20-056877-index.htm |
| 2020-05-05 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/894158/000110465920056927/0001104659-20-056927-index.htm |
| 2020-08-04 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/894158/000110465920090343/0001104659-20-090343-index.htm |
| 2020-08-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/894158/000110465920090908/0001104659-20-090908-index.htm |
| 2020-08-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/894158/000110465920091457/0001104659-20-091457-index.htm |
| 2020-08-06 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/894158/000110465920091503/0001104659-20-091503-index.htm |
| 2020-09-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/894158/000110465920106311/0001104659-20-106311-index.htm |
| 2020-10-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/894158/000110465920111398/0001104659-20-111398-index.htm |
| 2020-10-28 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/894158/000110465920119032/0001104659-20-119032-index.htm |
| 2019-04-03 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/894158/000114036119006440/0001140361-19-006440-index.htm |
| 2017-12-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/894158/000114420417064825/0001144204-17-064825-index.htm |
| 2017-12-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/894158/000114420417064828/0001144204-17-064828-index.htm |
| 2017-12-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/894158/000114420417064829/0001144204-17-064829-index.htm |
| 2017-12-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/894158/000114420417064830/0001144204-17-064830-index.htm |
| 2018-01-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/894158/000114420418001184/0001144204-18-001184-index.htm |
| 2018-02-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/894158/000114420418010096/0001144204-18-010096-index.htm |
| 2018-02-22 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/894158/000114420418010286/0001144204-18-010286-index.htm |
| 2018-03-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/894158/000114420418013351/0001144204-18-013351-index.htm |
| 2018-04-23 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/894158/000114420418021693/0001144204-18-021693-index.htm |
| 2018-05-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/894158/000114420418025766/0001144204-18-025766-index.htm |
| 2018-05-07 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/894158/000114420418025776/0001144204-18-025776-index.htm |
| 2018-05-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/894158/000114420418026138/0001144204-18-026138-index.htm |
| 2018-05-08 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/894158/000114420418026171/0001144204-18-026171-index.htm |
| 2018-05-14 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/894158/000114420418028259/0001144204-18-028259-index.htm |
| 2018-05-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/894158/000114420418030165/0001144204-18-030165-index.htm |
| 2018-08-01 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/894158/000114420418041398/0001144204-18-041398-index.htm |
| 2018-08-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/894158/000114420418041405/0001144204-18-041405-index.htm |
| 2018-08-01 | PRE 14A | Other preliminary proxy statements | https://www.sec.gov/Archives/edgar/data/894158/000114420418041412/0001144204-18-041412-index.htm |
| 2018-08-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/894158/000114420418042817/0001144204-18-042817-index.htm |
| 2018-08-08 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/894158/000114420418042887/0001144204-18-042887-index.htm |
| 2018-08-09 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/894158/000114420418042966/0001144204-18-042966-index.htm |
| 2018-08-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/894158/000114420418043710/0001144204-18-043710-index.htm |
| 2018-08-14 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/894158/000114420418044161/0001144204-18-044161-index.htm |
| 2018-08-16 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/894158/000114420418045084/0001144204-18-045084-index.htm |
| 2018-08-20 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/894158/000114420418045633/0001144204-18-045633-index.htm |
| 2018-09-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/894158/000114420418048214/0001144204-18-048214-index.htm |
| 2018-09-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/894158/000114420418048215/0001144204-18-048215-index.htm |
| 2018-09-18 | S-1 | General form for registration of securities under the Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/894158/000114420418049861/0001144204-18-049861-index.htm |
| 2018-09-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/894158/000114420418050928/0001144204-18-050928-index.htm |
| 2018-10-02 | S-1/A | General form for registration of securities under the Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/894158/000114420418052016/0001144204-18-052016-index.htm |
| 2018-10-02 | FWP | Filing under Securities Act Rules 163/433 of free writing prospectuses | https://www.sec.gov/Archives/edgar/data/894158/000114420418052018/0001144204-18-052018-index.htm |
| 2018-10-02 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/894158/000114420418052101/0001144204-18-052101-index.htm |
| 2018-10-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/894158/000114420418052119/0001144204-18-052119-index.htm |
| 2018-10-04 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/894158/000114420418052521/0001144204-18-052521-index.htm |
| 2018-10-04 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/894158/000114420418052523/0001144204-18-052523-index.htm |
| 2018-10-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/894158/000114420418053098/0001144204-18-053098-index.htm |
| 2018-10-10 | S-1/A | General form for registration of securities under the Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/894158/000114420418053149/0001144204-18-053149-index.htm |
| 2018-10-10 | S-1/A | General form for registration of securities under the Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/894158/000114420418053211/0001144204-18-053211-index.htm |
| 2018-10-12 | 424B4 | Prospectus [Rule 424(b)(4)] | https://www.sec.gov/Archives/edgar/data/894158/000114420418053648/0001144204-18-053648-index.htm |
| 2018-10-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/894158/000114420418053807/0001144204-18-053807-index.htm |
| 2018-11-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/894158/000114420418058370/0001144204-18-058370-index.htm |
| 2018-11-08 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/894158/000114420418058414/0001144204-18-058414-index.htm |
| 2018-11-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/894158/000114420418061119/0001144204-18-061119-index.htm |
| 2018-11-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/894158/000114420418062336/0001144204-18-062336-index.htm |
| 2018-12-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/894158/000114420418063398/0001144204-18-063398-index.htm |
| 2018-12-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/894158/000114420418063625/0001144204-18-063625-index.htm |
| 2018-12-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/894158/000114420418063627/0001144204-18-063627-index.htm |
| 2018-12-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/894158/000114420418063628/0001144204-18-063628-index.htm |
| 2018-12-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/894158/000114420418063630/0001144204-18-063630-index.htm |
| 2019-01-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/894158/000114420419000236/0001144204-19-000236-index.htm |
| 2019-02-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/894158/000114420419010544/0001144204-19-010544-index.htm |
| 2019-02-27 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/894158/000114420419010592/0001144204-19-010592-index.htm |
| 2019-03-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/894158/000114420419012008/0001144204-19-012008-index.htm |
| 2019-04-01 | 10-K/A | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/894158/000114420419017481/0001144204-19-017481-index.htm |
| 2019-05-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/894158/000114420419024512/0001144204-19-024512-index.htm |
| 2019-05-08 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/894158/000114420419024539/0001144204-19-024539-index.htm |
| 2019-07-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/894158/000114420419033241/0001144204-19-033241-index.htm |
| 2019-07-15 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/894158/000114420419034736/0001144204-19-034736-index.htm |
| 2019-08-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/894158/000114420419038566/0001144204-19-038566-index.htm |
| 2019-08-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/894158/000114420419038572/0001144204-19-038572-index.htm |
| 2019-08-08 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/894158/000114420419038590/0001144204-19-038590-index.htm |
| 2019-08-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/894158/000114420419041677/0001144204-19-041677-index.htm |
| 2019-09-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/894158/000114420419043618/0001144204-19-043618-index.htm |
| 2019-09-26 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/894158/000114420419046080/0001144204-19-046080-index.htm |
| 2019-02-05 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/894158/000139382519000099/0001393825-19-000099-index.htm |
| 2018-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/894158/000145307218000061/0001453072-18-000061-index.htm |
| 2019-01-17 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/894158/000153561019000054/0001535610-19-000054-index.htm |
| 2019-01-17 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/894158/000153561019000055/0001535610-19-000055-index.htm |
| 2020-01-21 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/894158/000153561020000046/0001535610-20-000046-index.htm |
| 2019-04-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/894158/000156761919008334/0001567619-19-008334-index.htm |
| 2018-05-15 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/894158/999999999518001264/9999999995-18-001264-index.htm |
| 2018-08-22 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/894158/999999999518002172/9999999995-18-002172-index.htm |
| 2018-10-10 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/894158/999999999518002587/9999999995-18-002587-index.htm |
Synthetic Biologics, Inc (SYN) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Synthetic Biologics, Inc (SYN). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 37%Institutional Ownership: 712%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2019-04-03 | RANDAL J KIRK | 10% Share Holder | Sell | 69,161.00 | 0.65 | 44,954.65 | 165,332.00 | https://www.sec.gov/Archives/edgar/data/894158/000156761919008334/0001567619-19-008334-index.htm |
| 2019-04-02 | RANDAL J KIRK | 10% Share Holder | Sell | 9,909.00 | 0.66 | 6,539.94 | 234,493.00 | https://www.sec.gov/Archives/edgar/data/894158/000156761919008334/0001567619-19-008334-index.htm |
| 2019-04-01 | RANDAL J KIRK | 10% Share Holder | Sell | 30,265.00 | 0.67 | 20,277.55 | 244,402.00 | https://www.sec.gov/Archives/edgar/data/894158/000156761919008334/0001567619-19-008334-index.htm |
| 2019-08-23 | SHALLCROSS STEVEN A | CEO and CFO | Buy | 50,000.00 | 0.42 | 20,785.00 | 50,000.00 | https://www.sec.gov/Archives/edgar/data/894158/000114420419041677/0001144204-19-041677-index.htm |
| 2019-04-03 | RANDAL J KIRK | 10% Share Holder | Sell | 26,080.00 | 0.65 | 16,952.00 | 62,342.00 | https://www.sec.gov/Archives/edgar/data/894158/000156761919008334/0001567619-19-008334-index.htm |
| 2019-04-02 | RANDAL J KIRK | 10% Share Holder | Sell | 3,737.00 | 0.66 | 2,466.42 | 88,422.00 | https://www.sec.gov/Archives/edgar/data/894158/000156761919008334/0001567619-19-008334-index.htm |
| 2019-04-01 | RANDAL J KIRK | 10% Share Holder | Sell | 11,413.00 | 0.67 | 7,646.71 | 92,159.00 | https://www.sec.gov/Archives/edgar/data/894158/000156761919008334/0001567619-19-008334-index.htm |